Efficacy of actinidin-containing kiwifruit extract Zyactinase on constipation: a randomised double-blinded placebo-controlled clinical trial

Iona Weir ； Quan Shu ； Nengding Wei MDChengkai Wei ； Yi Zhu

《Asia Pacific Journal of Clinical Nutrition》 27卷3期 (2018/03) Pp. 564-571

https://doi.org/10.6133/apjcn.122017.03

摘要

Background and Objectives: Zyactinase® is an extract of green kiwifruit, formulated into the consumer healthcare products marketed as Phloe® and Kivia, used to assist in the relief of the symptoms associated with a range of digestive system dysfunction, including constipation and Irritable Bowel Syndrome (IBS). Methods and Study Design: A randomised, double-blind, placebo-controlled clinical trial was undertaken to determine the effects of the kiwifruit extract on bowel movement, stool formation and IBS associated symptoms amongst a subject group of generally healthy individuals experiencing a period of moderate constipation. Fifty-eight participants were randomized to the kiwifruit extract (28) or placebo (30). Selection criterion was decreased number of bowel movements (＜3/week), with increased faecal hardness and IBS associated symptoms. The study ran for three weeks, with participants first undergoing a seven-day wash out period, followed by a seven-day dosing period, and then a seven-day follow up period. Results: There was a significant increase in the defecation frequency (p＜0.001), with a significant improvement in faecal score (p＜0.01). There was a significant difference in painful defecation and abdominal pain between the two groups (p＜0.01). No side effects, including diarrhoea, urgency or abdominal pain, were observed during the trial. Conclusions: The green kiwifruit extract significantly induced normal bowel movements with no adverse effects. The kiwifruit extract relieved constipation and the symptoms of IBS such as bloating, flatulence and abdominal pain.

關鍵字

kiwifruit ； constipation ； IBS ； actinidin ； Zyactinase